|
| Tuesday, September 19, 2017 |
|
|
Eisai Presents Results of Phase Iii Clinical Study of Lenvima (Lenvatinib) in Unresectable Hepatocellular Carcinoma at 11th ILCA Annual Conference |
| In the total population analysis of this study, the treatment effect of lenvatinib for all patients on the primary endpoint of Overall Survival (OS) was demonstrated by statistical confirmation of non-inferiority to sorafenib. more info >> |
|
| Wednesday, September 13, 2017 |
|
|
Eisai to Launch New "Etak Antimicrobial Spray Alpha" Containing Long-Acting Antimicrobial Agent Etak |
| Eisai Co., Ltd. will launch Etak Antimicrobial Spray Alpha (classified as miscellaneous goods), which contains long-acting antimicrobial agent Etak, on September 19. more info >> |
|
| Tuesday, September 12, 2017 |
|
|
Eisai and Mamorio to Jointly Launch "Me-Mamorio" Tracking Tool to Support People with Dementia and Seniors Going Out |
| Eisai Co., Ltd. and MAMORIO, Inc. have announced that the MeMAMORIO tracking tool to support people with dementia and seniors going out will be launched in Japan on September 13. more info >> |
|
|
Eisai Selected for Fifth Consecutive Year of Membership in Dow Jones Sustainability Asia Pacific Index 2017 |
| Eisai Co., Ltd. announced today that it has been selected for a fifth consecutive year of membership in the DJSI Asia Pacific, the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI). more info >> |
|
|
Eisai Presents New Quality of Life Findings in Hepatocellular Carcinoma Patients from Lenvatinib Versus Sorafenib Study in Oral Session at ESMO Congress |
| Eisai Co., Ltd. has announced that new findings indicating its in-house discovered and developed anticancer agent lenvatinib mesylate delays deterioration in certain areas of health-related quality of life (QOL) in comparison to sorafenib were presented in an oral session at the ESMO 2017 Congress, which took place in Madrid, Spain. more info >> |
|
|
Eisai Presents Results of Phase Ib/II Clinical Study of Lenvima (Lenvatinib) in Combination with Pembrolizumab for Renal Cell Carcinoma in Oral Session at ESMO 2017 Congress |
| Eisai Co., Ltd. announced today that an oral presentation on the results of the renal cell carcinoma cohort from a Phase Ib/II clinical study of its in-house discovered and developed multiple receptor tyrosine kinase inhibitor lenvatinib mesylate. more info >> |
|
| Friday, September 8, 2017 |
|
|
Conclusion of Development Collaboration Agreement for Lenvima (Lenvatinib Mesylate) and Opdivo (Nivolumab) Combination Therapy for Treatment of Hepatocellular Carcinoma |
| Based on this agreement, Eisai and Ono will swiftly implement a Phase Ib clinical trial in Japan to investigate the safety, tolerability, and efficacy of the combination of Lenvima and Opdivo in patients with HCC. more info >> |
|
| Wednesday, September 6, 2017 |
|
|
Eisai Signs Agreement with Merck & Co. to Expand Enrollment of Combination Study for Lenvima (Lenvatinib) and Pembrolizumab Due to Encouraging Initial Data in Endometrial Carcinoma |
| The decision to expand the target number of enrolled patients is based on favourable interim analysis results of the endometrial cohort in a Phase Ib/II study (Study 111) of lenvatinib in combination with pembrolizumab for multiple solid cancers, which is being jointly conducted by Eisai and Merck & Co., Inc. more info >> |
|
|
Eisai Signs Agreement with Merck & Co. to Expand Enrollment of Study for Halaven (Eribulin) and Pembrolizumab Combination Due to Encouraging Initial Data in Triple-Negative Breast Cancer |
| The decision to expand the target number of enrolled patients is based on favourable interim analysis results of a Phase Ib/II study (Study 218) of eribulin in combination with pembrolizumab for metastatic triple-negative breast cancer, which is being jointly conducted by Eisai and Merck & Co., Inc, Kenilworth, NJ, U.S.A. more info >> |
|
| Friday, September 1, 2017 |
|
|
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2017 Congress Three Abstracts on Lenvima (Lenvatinib) to be Presented in Oral Session |
| Eisai Co., Ltd. announced today that a series of abstracts will be presented during the European Society for Medical Oncology (ESMO) 2017 Congress , taking place in Madrid, Spain, from September 8 to 12, 2017. more info >> |
|
|
|
